Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic
A new 24-month subgroup analysis looked at sustained clinical response in participants who received up to two doses of RBX2660…
-
-
Ferring Pharmaceuticals Announces the Launch of FertilityWise – a New, On-Demand E-Learning Program for Fertility Clinic Staff
In collaboration with a multi-disciplinary team of leading experts, FertilityWise offers a convenient, tech-based solution for fertility information. This new…
-
Ferring Presents New Subgroup Analyses of Health-Related Quality of Life and Safety and Efficacy Data at IDWeek 2022 for RBX2660
Subgroup analysis of Phase 3 trial (PUNCH™ CD3) looked at health-related quality of life data in patients treated with RBX2660…
-
Ferring Pharmaceuticals to Present New Data Highlighting Future Assisted Reproductive Technology Market Trends at ASRM 2022 Scientific Congress & Expo
Findings from the analysis underscore Ferring’s commitment to identifying and addressing the needs of healthcare professionals and fertility clinic staff…
-
Ferring Introduces Fertility Outreach, a Text-based Platform Providing Aspiring Parents with Access to a Live Fertility Coach
Created in partnership with Robyn, a community-driven digital platform, Fertility Outreach evolves the fertility journey by providing a text-based solution…
-
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022
Parsippany, NJ – October 11, 2022 – Ferring Pharmaceuticals today announced it will present data from new analyses of RBX2660, an…
-
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at IDWeek 2022
Parsippany, NJ – October 6, 2022 – Ferring Pharmaceuticals today announced they will present analyses of RBX2660, an investigational microbiota-based live…
-
Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
Vaccines and Related Biological Products Advisory Committee reviewed data from the biologics license application for RBX2660 RBX2660 is an investigational…
-
Partnering to Help Drive Reproductive Medicine and Maternal Health Forward
Ferring to share insights and expertise across a range of timely and critical topics at the Women’s Health Innovation Summit…
-
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
Vaccines and Related Biological Products Advisory Committee will hold meeting on September 22, 2022 RBX2660 is an investigational microbiota-based live…